1. Historical evidence for economic effects of COVID-19

   • Rahmiye Figen Ceylan
   • Burhan Ozkan
   • Esra Mulazimogullari

   Editorial 04 June 2020 Pages: 817 - 823

2. Cost-effectiveness of a non-pharmacological treatment vs. “care as usual” in day care centers for community-dwelling older people with cognitive impairment: results from the German randomized controlled DeTaMAKS-trial

   • Kathrin Steinbeisser
   • Larissa Schwarzkopf
   • Hildegard Seidl

   Original Paper Open access 26 March 2020 Pages: 825 - 844

   

3. A novel method for predicting the budget impact of innovative medicines: validation study for oncolytics

   • Joost W. Geenen
   • Svetlana V. Belitser
   • Anke M. Hövels

   Original Paper Open access 04 April 2020 Pages: 845 - 853

   

4. The pass-through of alcohol excise taxes to prices in OECD countries

   • Ce Shang
   • Anh Ngo
   • Frank J. Chaloupka

   Original Paper 31 March 2020 Pages: 855 - 867

   

5. Health-related quality of life in elderly people with hypertension and the estimation of minimally important difference using EQ-5D-5L in Hong Kong SAR, China

   • Eliza Lai Yi Wong
   • Richard Huan Xu
   • Annie Wai Ling Cheung

   Original Paper 02 April 2020 Pages: 869 - 879

   

6. Determination of the target population in early benefit assessments in Germany: challenges for non-small-cell lung cancer

   • C. ten Thoren
   • C. Balg
   • A. Schwalm

   Original Paper Open access 31 March 2020 Pages: 881 - 893

   

7. A retrospective analysis of budget impact models submitted to the National Centre for Pharmacoeconomics in Ireland

   • Felicity Lamrock
   • Laura McCullagh
   • Michael Barry

   Original Paper Open access 30 March 2020 Pages: 895 - 901

   

8. Does linear equating improve prediction in mapping? Crosswalking MacNew onto EQ-5D-5L value sets

   • Admassu N. Lamu

   Original Paper Open access 16 April 2020 Pages: 903 - 915

   

9. How expensive are post-traumatic stress disorders? Estimating incremental health care and economic costs on anonymised claims data

   • Tim Bothe
   • Josephine Jacob
   • Jochen Walker

   Original Paper Open access 26 May 2020 Pages: 917 - 930

   

10. Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations

    • Lotte Westerink
    • Jelmer L. J. Nicolai
    • Maarten J. Postma

    Original Paper Open access 23 April 2020 Pages: 931 - 943

    

11. The effect of time to death on health care expenditures: taking into account the endogeneity and right censoring of time to death

    • Christophe Kolodziejczyk

    Original Paper 23 April 2020 Pages: 945 - 962

12. Lifetime cost of unilateral cochlear implants in adults: a Monte Carlo simulation

    • Christin Thum
    • Thomas Lenarz
    • Steffen Fleßa

    Original Paper 24 April 2020 Pages: 963 - 975